Bristol-Myers Suspends Hepatitis C Drug Clinical Trial Businessweek Bristol-Myers Squibb Co. (BMY) (BMY) said it suspended a mid-stage study of an experimental hepatitis C drug obtained in its $2.5 billion January acquisition of Inhibitex Inc. after a patient developed heart failure. Bristol-Myers suspended the ... Bristol's Hep C Drug Blow Up May Benefit Gilead, Idenix, Vertex Pharma Bristol-Myers: hepatitis C drug trial hit by safety issue |
Wednesday, August 1, 2012
Bristol-Myers Suspends Hepatitis C Drug Clinical Trial - Businessweek
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment